Entering text into the input field will update the search result below

Glaxo's Nucala successful in pivotal nasal polyp study

Apr. 03, 2020 9:24 AM ETGSK plc (GSK) StockGSKBy: Douglas W. House, SA News Editor4 Comments
  • GlaxoSmithKline (NYSE:GSK) announces a positive outcome from a Phase 3 clinical trial, SYNAPSE, evaluating Nucala (mepolizumab) plus standard-of-care treatment in patients with chronic rhinosinusitis with nasal polyps.
  • The study met both co-primary endpoints demonstrating statistically significant improvements in the size of nasal polyps at week 52 and nasal obstruction during weeks 49-52.
  • A key secondary endpoint, the time to first actual nasal surgery up to week 52, was also met.
  • Regulatory filings are next up.
  • Nucala was first approved in the U.S. in November 2015 for asthma.
  • Shares down 2% premarket on light volume.

Recommended For You

About GSK Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
GSK--
GSK plc